BiotechTube

Bempedoic Acid + Ezetimibe + Placebos

Phase 3Completed
0 watching 0 views this week📈 Rising
72
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hyperlipidemias

Conditions

Hyperlipidemias

Trial Timeline

Oct 23, 2017 → Jul 18, 2018

NCT ID
NCT03337308

About Bempedoic Acid + Ezetimibe + Placebos

Bempedoic Acid + Ezetimibe + Placebos is a phase 3 stage product being developed by Esperion Therapeutics for Hyperlipidemias. The current trial status is completed. This product is registered under clinical trial identifier NCT03337308. Target conditions include Hyperlipidemias.

Hype Score Breakdown

Clinical
27
Activity
18
Company
5
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT03337308Phase 3Completed

Competing Products

5 competing products in Hyperlipidemias

See all competitors
ProductCompanyStageHype Score
Evolocumab + Statins (Cardiovascular Agents)AmgenApproved
84
atorvastatin + atorvastatin + atorvastatinPfizerApproved
84
SAL003 140 mg + PlaceboShenzhen Salubris PharmaceuticalsPhase 3
76
SAL003 140 mg + PlaceboShenzhen Salubris PharmaceuticalsPhase 3
76
SLN360 + PlaceboMedpacePhase 1
30

Other Products from Esperion Therapeutics

Bempedoic Acid / Ezetimibe Oral Tablet + PlaceboApproved
80
Bempedoic Acid 180 MG Oral Tablet + Bempedoic Acid/Ezetimibe 180 MG-10 MG Oral TabletApproved
80
Bempedoic acid + EzetimibePhase 3
72
bempedoic acidPhase 3
72
Bempedoic acid 180 mg tablet + Matching placebo tabletPhase 3
72